NASDAQ:ONCY Oncolytics Biotech (ONCY) Stock Price, News & Analysis $1.00 -0.01 (-0.95%) (As of 09:36 AM ET) Add Compare Share Share Today's Range$0.99▼$1.0250-Day Range$0.99▼$1.2452-Week Range$0.88▼$3.37Volume44,156 shsAverage Volume303,829 shsMarket Capitalization$76.34 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Oncolytics Biotech alerts: Email Address Oncolytics Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside299.8% Upside$4.00 Price TargetShort InterestHealthy0.89% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.29) to ($0.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.60 out of 5 starsMedical Sector844th out of 896 stocksPharmaceutical Preparations Industry400th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingOncolytics Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOncolytics Biotech has only been the subject of 1 research reports in the past 90 days.Read more about Oncolytics Biotech's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.89% of the outstanding shares of Oncolytics Biotech have been sold short.Short Interest Ratio / Days to CoverOncolytics Biotech has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncolytics Biotech has recently increased by 2.52%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOncolytics Biotech does not currently pay a dividend.Dividend GrowthOncolytics Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONCY. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Oncolytics Biotech this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for ONCY on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of Oncolytics Biotech is held by insiders.Percentage Held by InstitutionsOnly 6.82% of the stock of Oncolytics Biotech is held by institutions.Read more about Oncolytics Biotech's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Oncolytics Biotech are expected to decrease in the coming year, from ($0.29) to ($0.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncolytics Biotech is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncolytics Biotech is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncolytics Biotech has a P/B Ratio of 3.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Oncolytics Biotech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About Oncolytics Biotech Stock (NASDAQ:ONCY)Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Read More ONCY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONCY Stock News HeadlinesJune 29, 2024 | americanbankingnews.comHead to Head Review: AnaptysBio (NASDAQ:ANAB) and Oncolytics Biotech (NASDAQ:ONCY)June 27, 2024 | prnewswire.comOncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer ProgramJuly 5, 2024 | True Market Insiders (Ad)Exposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…June 24, 2024 | prnewswire.comOncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of AbsenceJune 20, 2024 | prnewswire.comOncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic CancerMay 24, 2024 | msn.comAdvancements in Cancer Therapeutics: What to Expect from the Upcoming 2024 Oncology ConferenceMay 24, 2024 | finance.yahoo.comOncolytics Biotech Says ASCO Abstracts Highlight Pelareorep's Treatment Potential in Pancreatic CancerMay 24, 2024 | prnewswire.comOncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of ActionJuly 5, 2024 | True Market Insiders (Ad)Exposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…May 16, 2024 | prnewswire.comOncolytics Biotech® Announces Voting Results from the Annual General Meeting of ShareholdersMay 15, 2024 | prnewswire.comOncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer TrialMay 10, 2024 | finance.yahoo.comOncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2024 Earnings Call TranscriptMay 9, 2024 | prnewswire.comOncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational HighlightsMay 9, 2024 | prnewswire.comOncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic CancerMay 8, 2024 | prnewswire.comOncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare ConferenceApril 30, 2024 | finanznachrichten.deUSA News Group: As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up ResponseApril 30, 2024 | baystreet.caBiotech Firms Intensify Efforts as Breast Cancer Strikes Younger Patients at Alarming RateApril 30, 2024 | prnewswire.comOncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational HighlightsApril 25, 2024 | finanznachrichten.deOncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual MeetingApril 25, 2024 | prnewswire.comOncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual MeetingApril 21, 2024 | theglobeandmail.comClosing Bell: Oncolytics Bio up on Friday (ONC)April 13, 2024 | theglobeandmail.comBiotech Breakthroughs Spearhead Fight Against Rising Breast Cancer CasesApril 11, 2024 | finanznachrichten.deUSA News Group: Biotech Innovations Paving the Way in Breast Cancer FightApril 11, 2024 | msn.comOncolytics seeking FDA meeting to discuss registration-enabling studyApril 11, 2024 | prnewswire.comOncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDAMarch 14, 2024 | finanznachrichten.deUSA News Group: Biotech's Role in Addressing the Pancreatic Cancer EmergencyMarch 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Oncolytics Biotech Amidst Promising Pipeline and Advancements in Cancer Treatment TrialsSee More Headlines Receive ONCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/04/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ONCY CUSIPN/A CIK1129928 Webwww.oncolyticsbiotech.com Phone(403) 670-7377Fax403-283-0858Employees29Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+296.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,560,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-110.66% Return on Assets-74.28% Debt Debt-to-Equity RatioN/A Current Ratio8.13 Quick Ratio8.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book3.74Miscellaneous Outstanding Shares76,310,000Free Float76,235,000Market Cap$77.07 million OptionableNot Optionable Beta1.91 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Matthew C. Coffey M.B.A.Ph.D., President, CEO & DirectorMr. Kirk J. Look C.A.CA, Chief Financial OfficerDr. Thomas C. Heineman M.D.Ph.D., Chief Medical OfficerMs. Allison Hagerman P.Eng.P.M.P., Vice President of Product DevelopmentMs. Amy Goodowitz Levin B.S.N.R.N., Vice President of Clinical OperationsJon PattonDirector of Investor Relations & CommunicationMr. John Mark Lievonen BBAC.M., FCA, LLD, MBA, ConsultantMore ExecutivesKey CompetitorsEnlivex TherapeuticsNASDAQ:ENLVOrgenesisNASDAQ:ORGSChembio DiagnosticsNASDAQ:CEMIALX OncologyNASDAQ:ALXOAlto NeuroscienceNYSE:ANROView All CompetitorsInstitutional OwnershipVirtu Financial LLCBought 51,889 shares on 5/20/2024Ownership: 0.068%View All Institutional Transactions ONCY Stock Analysis - Frequently Asked Questions Should I buy or sell Oncolytics Biotech stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ONCY shares. View ONCY analyst ratings or view top-rated stocks. What is Oncolytics Biotech's stock price target for 2024? 3 brokerages have issued 1 year price targets for Oncolytics Biotech's shares. Their ONCY share price targets range from $3.00 to $5.00. On average, they anticipate the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 299.8% from the stock's current price. View analysts price targets for ONCY or view top-rated stocks among Wall Street analysts. How have ONCY shares performed in 2024? Oncolytics Biotech's stock was trading at $1.35 at the beginning of 2024. Since then, ONCY shares have decreased by 25.9% and is now trading at $1.0004. View the best growth stocks for 2024 here. When is Oncolytics Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our ONCY earnings forecast. How were Oncolytics Biotech's earnings last quarter? Oncolytics Biotech Inc. (NASDAQ:ONCY) issued its earnings results on Thursday, May, 9th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.02. What is Brad Thompson's approval rating as Oncolytics Biotech's CEO? 2 employees have rated Oncolytics Biotech Chief Executive Officer Brad Thompson on Glassdoor.com. Brad Thompson has an approval rating of 56% among the company's employees. This puts Brad Thompson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), KushCo (KSHB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT). How do I buy shares of Oncolytics Biotech? Shares of ONCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ONCY) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersUrgent Alert: Is the U.S. Implementing a Digital Dollar?Our exclusive guide, "Exploring the Future of the U.S. Dollar in a Digital World," is your essential resource ...Gold Gate Capital | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredDOLLAR RECALL ON THE AGENDAHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming...Golden Crest | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.